Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations.

Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE.

PLoS One. 2012;7(6):e39754. doi: 10.1371/journal.pone.0039754. Epub 2012 Jun 28.

2.

Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.

Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A.

Antimicrob Agents Chemother. 2012 Apr;56(4):1990-6. doi: 10.1128/AAC.06272-11. Epub 2012 Jan 30.

3.

Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.

Zhu C, Zhang Y, Shen Y, Siu GK, Wu W, Qian X, Deng G, Xu Y, Lau R, Fan X, Zhang W, Lu H, Yam WC.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):260-3. doi: 10.1016/j.diagmicrobio.2012.03.025. Epub 2012 May 4.

PMID:
22560167
4.

Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM.

Antimicrob Agents Chemother. 2006 Jan;50(1):104-12.

5.

DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, Reitter D, Jarlier V, Mayer C, Aubry A.

Antimicrob Agents Chemother. 2011 Oct;55(10):4524-9. doi: 10.1128/AAC.00707-11. Epub 2011 Jul 18.

6.

Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.

Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM.

J Med Microbiol. 2013 Jan;62(Pt 1):108-13. doi: 10.1099/jmm.0.046821-0. Epub 2012 Sep 27.

PMID:
23019190
7.
8.

High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.

Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR.

J Clin Microbiol. 2012 Apr;50(4):1390-6. doi: 10.1128/JCM.05286-11. Epub 2011 Dec 21.

9.

Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.

Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA.

Antimicrob Agents Chemother. 2009 Oct;53(10):4498-500. doi: 10.1128/AAC.00287-09. Epub 2009 Aug 17.

10.
11.

Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N.

Antimicrob Agents Chemother. 2013 Sep;57(9):4496-500. doi: 10.1128/AAC.00506-13. Epub 2013 Jul 8.

12.

Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.

Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T.

PLoS One. 2015 Mar 27;10(3):e0120470. doi: 10.1371/journal.pone.0120470. eCollection 2015. Review.

13.

gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China.

Long Q, Li W, Du Q, Fu Y, Liang Q, Huang H, Xie J.

Int J Antimicrob Agents. 2012 Jun;39(6):486-9. doi: 10.1016/j.ijantimicag.2012.02.015. Epub 2012 Apr 21.

PMID:
22526012
14.

Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.

Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC.

J Antimicrob Chemother. 2007 May;59(5):860-5. Epub 2007 Apr 5.

PMID:
17412727
15.

Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.

Suzuki Y, Nakajima C, Tamaru A, Kim H, Matsuba T, Saito H.

Int J Antimicrob Agents. 2012 May;39(5):435-9. doi: 10.1016/j.ijantimicag.2012.01.007. Epub 2012 Mar 13.

PMID:
22421328
16.

Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, Singh M.

J Antibiot (Tokyo). 2015 Jan;68(1):63-6. doi: 10.1038/ja.2014.95. Epub 2014 Jul 23.

PMID:
25052485
17.

High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.

Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S.

J Antimicrob Chemother. 2006 Dec;58(6):1264-7. Epub 2006 Oct 3.

PMID:
17018563
18.

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M.

J Clin Microbiol. 2016 Mar;54(3):727-33. doi: 10.1128/JCM.02775-15. Epub 2016 Jan 13.

19.

Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.

Duong DA, Nguyen TH, Nguyen TN, Dai VH, Dang TM, Vo SK, Do DA, Nguyen VV, Nguyen HD, Dinh NS, Farrar J, Caws M.

Antimicrob Agents Chemother. 2009 Nov;53(11):4835-9. doi: 10.1128/AAC.00541-09. Epub 2009 Aug 31.

20.

Supplemental Content

Support Center